Amylyx’s Avexitide Hits Phase III Endpoint for Post-Bariatric Hypoglycemia

Company: Amylyx Pharmaceuticals · Event Type: Phase III Topline Data · Product: Avexitide · Mechanism: GLP-1 Receptor Antagonist · Indication: Post-Bariatric Hypoglycemia · Announcement Date: August 18, 2026 Summary Amylyx reported that avexitide met the FDA-agreed primary endpoint in the 78-participant Phase III LUCIDITY trial…